atomoxetine


Also found in: Medical, Wikipedia.
Related to atomoxetine: Atomoxetine hydrochloride
Translations

atomoxetine

n atomoxetina
References in periodicals archive ?
A randomized controlled trial of pediatric patients with both ADHD and an anxiety disorder showed reductions in both symptom domains with atomoxetine dosed at an average of 1.
The increase in the percentage of women prescribed ADHD medications was confined to a rise in the prescribing of stimulant medications ([dagger]) (388% increase from 2003 to 2015); the percentage of women prescribed the nonstimulant medication atomoxetine was stable over time (0% change from 2003 to 2015) (Figure).
items : Acetyl Salicylic Acid + Clopidogrel Tab, Acitretin Cap Ip, Acyclovir Inj Ip, Adapalene Gel, Alteplase Inj, Amisulpride Tab Ip, Amphotericin B Liposomal Inj, Artesunate +(SULPHADOXINE + Pyremethamine, Atomoxetine Tab, Barium Sulphate Suspension, Benfotiamine Tab, Biotin Tab, Botulinum Toxin A Inj (FREEZE-DRIED Powder For Injection), Botulinum Toxin A Inj (FREEZE-DRIED Powder For Injection), Budesonide Controlled Release Tab, Buprenorphine Inj Ip, Bupropion Tab, Caffeine Citrate Inj Bp/Usp, Carbimazole Tab Ip, Cilostazol Tab Ip, Citicoline Inj, Clarithromycin Tab Ip.
Apotex, Teva Pharmaceuticals USA, Aurobindo Pharma, and Glenmark Pharmaceuticals all gained approval to market generic atomoxetine at various strengths.
The companies have gained approval to market atomoxetine in multiple strengths for the treatment of attention-deficit/hyperactivity disorder (ADHD) in paediatric and adult patients.
17% Prescribe naltrexone, 50 mg/d, to decrease until alcohol use is stabilized, then titrate atomoxetine to 80mg/dfbrADHD symptoms 7% Prescribe naltrexone, 50 mg/d, and encourage J and his parents to attend 12-step meetings 8% Prescribe disulfiram, 500 mg/d, for 1 to 2 weeks, then reduce to 250 mg/d, and start cognitive-behavioral therapy 68% Educate J on the dangers of abusing alcohol, and start regular screenings for substance use
The newly released figures, which cover the period 2010 to 2012, relate to the recommended drugs used to treat ADHD - methylphenidate, atomoxetine and dexamfetamine.
Non-stimulant medication licensed for use in ADHD is atomoxetine.
Treatment guidelines of the National Institute for Health and Clinical Excellence (NICE) on methylphenidate, atomoxetine and dexamphetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents [6]
EB-1020 has a norepinephrine profile similar to the pharmacology of the first-generation non-stimulant atomoxetine, but unlike atomoxetine, EB-1020 adds moderate dopamine neurotransmission that is believed to offer the potential for improved efficacy in ADHD.
Non-stimulant medications include atomoxetine (Strattera) and Guanfacine (Intuniv).
To determine whether the higher blood pressure and increases in heart rate often associated with ADHD medications might increase risk for cardiovascular disease, researchers analyzed data on 150,359 adults with ADHD who were taking methylphenidate (Ritalin, Concerta), atomoxetine (Strattera), or amphetamine (Adderall) over a period of up to 19 years.